WESTMINSTER — Arca Biopharma Inc. (Nasdaq: ABIO) said it had almost $67 million in cash on hand at the end of the first quarter of 2021 to fund its clinical research into a possible treatment for some patients with deadly reactions to COVID-19 infections.
The Westminster company reported having just more than $66.93 million in cash and equivalents on hand. It has no revenues, as the company doesn’t have any drugs approved for use by physicians yet.
The company also posted a $4.1 million loss for the period, a 206% increase over the same period last year. The majority of that increased losses came from increased research and development costs.
Arca’s flagship drug candidate is AB-201, which was originally designed as an anti-clotting treatment for patients who had suffered heart attacks or other cardiac events. The company repurposed the drug for potential use as an anti-inflammatory and anti-clotting agent to combat those symptoms seen in some patients suffering from severe bouts of COVID-19.
Results for the Phase II trial for AB-201 in COVID patients are due in the third quarter of the year.
© 2021 BizWest Media LLC
WESTMINSTER — Arca Biopharma Inc. (Nasdaq: ABIO) said it had almost $67 million in cash on hand at the end of the first quarter of 2021 to fund its clinical research into a possible treatment for some patients with deadly reactions to COVID-19 infections.
The Westminster company reported having just more than $66.93 million in cash and equivalents on hand. It has no revenues, as the company doesn’t have any drugs approved for use by physicians yet.
The company also posted a $4.1 million loss for the period, a 206% increase over the same period last year. The majority of that increased losses came from increased research and development costs.
Arca’s flagship drug candidate is AB-201, which was originally designed as an anti-clotting treatment for patients who had suffered heart attacks or other cardiac events. The company repurposed the drug for potential use as an anti-inflammatory and anti-clotting agent to combat those symptoms seen in some patients suffering from severe bouts of COVID-19.
Results for the Phase II trial for AB-201 in COVID patients are due in the third quarter of the year.
© 2021 BizWest Media LLC
…
This article has been intentionally blurred.
You must purchase a subscription to view the rest of this content.
Want to See More!?
OR
Start your subscription to BizWest, The Business Journal of the Boulder Valley and Northern Colorado, TODAY!
Online access PLUS print versions of all Bizwest publications
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-month subscription to BizWest & all of the publications in print version.
Online access for one year.
One month subscription includes:
- 1-month online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
Online and print versions of all Bizwest publications PLUS premium access to BizWest Datastore for one year.
One year subscription includes:
- 1-year online access to BizWest.com which includes unlimited news stories, archived story access and interactive versions of monthly business journal.
- 1-year subscription to BizWest & all of the publications in print version.
- 1-year premium online access to unlimited downloads from the BizWest Datastore!
- 1-year premium online access to the ALL NEW Breaking Ground website!